Clinical evaluation of onset of analgesia using intravenous pamidronate in metastatic bone pain [6]

Journal of Pain and Symptom Management

Volumn 24, Issue 3, 2002, Pages 281-284

  Petcu, Eugen B ^a   Schug, Stephan A ^b   Smith, Rachel H ^b  

^a BOSTON MEDICAL CENTER   (United States)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; OPIATE; PAMIDRONIC ACID;

ADVANCED CANCER; ANALGESIA; ANALYSIS OF VARIANCE; BLOOD ANALYSIS; BONE METASTASIS; BREAST CARCINOMA; CANCER HORMONE THERAPY; CANCER PAIN; CANCER RADIOTHERAPY; CLINICAL TRIAL; COLON CARCINOMA; CONFUSION; DOSE TIME EFFECT RELATION; DROWSINESS; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; EVALUATION; FRACTURE; HUMAN; HYPERCALCEMIA; LETTER; LUNG CARCINOMA; MULTIPLE MYELOMA; PAIN; PAIN ASSESSMENT; PATIENT MOBILITY; PRACTICE GUIDELINE; PROGNOSIS; PROSTATE CARCINOMA; QUALITY OF LIFE; SEDATION; SIDE EFFECT; TREATMENT OUTCOME; WELLBEING; WORLD HEALTH ORGANIZATION;

ANALGESIA; ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; DIPHOSPHONATES; HUMAN; INJECTIONS, INTRAVENOUS; PAIN; PALLIATIVE CARE;

EID: 0036758243     PISSN: 08853924     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0885-3924(02)00478-5     Document Type: Letter

References (10)

1. Fulfaro F., Casuccio A., Ticozzi C.et al. The role of bisphosphonates in the treatment of painful metastastic bone disease. a review of phase III trial Pain. 78:1998;157-169.
2. Bloomfield D.J. Should bisphosphonates be part of the standard therapy of patients with multiple myeloma or bone metastases from other cancers? An evidence-based review. J Clin Oncol. 16:1998;1218-1225.
3. Cleeland C.S., Ryan K.M. Pain assessment. global use of the Brief Pain Inventory Ann Acad Med Sing. 23:1994;129-138.
4. Thurlimann B., Morant R., Jungi W.F., Radziwill A. Pamidronate for pain control in patients with osteolytic bone disease. a prospective dose-effect study Support Care Cancer. 2:1994;61-65.
5. Nussbaum S.R., Younger J., VandePol C.J.et al. Single-dose intravenous therapy with pamidronate for the treatment of hypercalcemia of malignancy. comparison of 30-, 60- and 90-mg dosages Am J Med. 95:1993;297-304.
6. Berenson J.R., Lichtenstein A., Porter L.et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N Engl J Med. 334:1996;488-493.
7. Thiebaud D., Leyvraz S., Von Fliedner V.et al. Treatment of bone metastases from breast cancer and myeloma with pamidronate. Eur J Cancer. 27:1991;37-41.
8. Mercadante S., Villari P., Ferrera P., Dabbene M. Pamidronate in incident pain due to bone metastases. J Pain Symptom Manage. 22:2001;630-631.
9. Conte P.F., Giannessi P.G., Latreille J.et al. Delayed progression of bone metastases with pamidronate therapy in breast cancer patients. a randomized, multicenter phase III trial Ann Oncol. 5:1994;41-44.
10. Tyrrell C.J. Role of pamidronate in the management of bone metastases from breast cancer. results of a noncomparative muticenter Phase II trial Ann Oncol. 5:1994;37-40.